ASTEX ANNOUNCES IND APPROVAL FOR AT9283

Astex Therapeutics has reported that the FDA has approved its investigational new drug (IND) application for the clinical development of its proprietary aurora kinase inhibitor, AT9283, for the treatment of cancer.

AT9283 was discovered and developed internally using the company's fragment-based drug discovery platform, Pyramid.

An initial Phase I study on AT9283 in hematological cancers will be conducted at one of the world's leading oncology centers in the U.S., the company said, and additional studies in North America and Europe are planned for the second half of the year.